The Experts below are selected from a list of 30 Experts worldwide ranked by ideXlab platform
D Sturchler - One of the best experts on this subject based on the ideXlab platform.
-
prevention of plasmodium falciparum malaria by Fansimef and lariam in the northeastern part of thailand
Southeast Asian Journal of Tropical Medicine and Public Health, 1993Co-Authors: C Eamsila, M L Mittelholzer, P Singharaj, P Yooyen, P Chatnugrob, Nopavong Na Ayuthya A, H K Webster, R Lasserre, D SturchlerAbstract:Two studies were conduct in Thailand in order to find appropriate falciparum malaria prophylactic drug regimens. The first study was done during June - September 1987 with 363 soldiers who received Fansimef (MSP) 1 tab/week (group 1), 337 soldiers who received MSP 1 tab/2 week (group 2) and 165 soldiers who received chloroquine 300 mg base weekly plus Fansidar 1 tab/week (group 3). At the end of the study there were 9 and 13 falciparum malaria episodes in groups 1 and 2, respectively, with incidence rates of 0.8 and 1.8 cases/100 person-months (P-M). In group 3, the corresponding values were 30 episodes and an incidence of 7.2/100 P-M. For the second study which lasted from October 1987 - January 1988 in the same area, 498 soldiers were given Fansimef 1/2 tab/week (group 4), 499 soldiers were given Lariam 1/2 tab/week (group 5) and 247 soldiers were given chloroquine plus Fansidar (group 6). Thirty malaria episodes were found in group 4, for an incidence of 2.0/100 P-M. In group 5, 23 episodes were found, for an incidence of 1.6/100 P-M. In group 6, 74 episodes occurred, ie an incidence of 12.2/100 P-M. The incidence rates of malaria among Fansimef 1 tab weekly, Fansimef half dose weekly or Lariam half dose weekly were not significantly different but were different from chloroquine plus Fansidar groups. Adverse events in each group were mild.
-
mefloquine sulphadoxine pyrimethamine Fansimef roche in the prophylaxis of plasmodium falciparum malaria a double blind comparative placebo controlled study
Annals of Tropical Medicine and Parasitology, 1992Co-Authors: L A Salako, R A Adio, M L Mittelholzer, D Sturchler, O Walker, A Sowunmi, R Reberliske, U DickschatAbstract:From July 1987 to June 1988 a randomized, double-blind, comparative placebo-controlled field trial was conducted in a group of villages near Ibadan, Nigeria. The aim of the study was to assess the ...
-
Fansimef for prophylaxis of malaria a double blind randomized placebo controlled trial
Southeast Asian Journal of Tropical Medicine and Public Health, 1992Co-Authors: D Bunnag, S Malikul, S Chittamas, D Chindanond, T Harinasuta, M Fernex, M L Mittelholzer, S Kristiansen, D SturchlerAbstract:At a time when Fansimef'li', the fixed combination of mefloquine, sulfadoxine and pyri methamine was considered for prophylaxis of falciparum malaria, a randomized double-blind study comparing the efficacy and tolerability of Fansimef'li' with that of Lariam® (mefloquine), Fan sidar®, chloroquine and placebo in malaria prophylaxis was performed in Thailand from July 1987 to January 1988. The study population of 602 adult males was recruited in Pak Tongchai District, some 360 km North-East of Bangkok, where multiresistant P. Jalciparum is endemic. All active treatments and placebo were given once weekly for 24 weeks with doses as follows: Fansimef: 125 mg mefloquine + 250 mg sulfadoxine + 12.5 mg pyrimethamine (I half-strength tablet); Lariam: 125 mg mefloquine (I half-strength tablet); Fansidar: 500 mg sulfadoxine + 25 mg pyrimethamine; chloroquine; 300 mg. A loading dose of 2 half-strength tablets was given in the Fansimef group in weeks I and 2 and in the Lariam group in weeks I to 4. The incidence of acute episodes of P. Jalciparum per 100 person months of prophylaxis was 0.17 each in the Fansimef and the Lariam groups, 1.18 in the Fansidar group, 0.69 in the chloroquine group and 0.64 in the placebo group (differences statistically not significant). Clinically adverse events were reported by 170 subjects (Fansimef 28, Lariam 29, Fansidar 41, choroquine 43, placebo 29; differences statistically not significant). The most frequent adverse events in all groups were headache, sleepiness, dizziness and weakness. There were five adverse events that led to premature discontinuation: I each in the placebo, chloroquine and Fansidar groups and 2 in the Lariam group (breathing difficulties, dizziness, dull head, feeling feverish, weakness and "less active"). In this setting Fansimef and Lariam offered an approximately four-fold higher protection than Fansidar or chloroquine which resembled placebo in their effect. The safety of low Fansimef and Lariam prophylactic doses was similar to placebo.
Jean Pierre Gnassounou - One of the best experts on this subject based on the ideXlab platform.
-
traitement de l acces palustre simple en pediatrie interet de Fansimef
Médecine d'Afrique noire, 1992Co-Authors: J Andoh, J Ouhon, Jean Pierre GnassounouAbstract:62 enfants âges de 6 mois a 16 ans, vivant dans l'agglomeration urbaine d'Abidjan, souffrant d'acces simples de paludisme a Plasmodium falciparum, confirmes parasitologiquement (>500 trophoizoites et/ou schizontes/mm3) ont recu un traitement par l'association mefloquine-sulfadoxine-pyrimethamine (Fansimef®) a la dose de 1/2 comprime pour 10 kg de poids en dose unique. 66,12% des enfants inclus ont fait l'objet d'un traitement antipaludique anterieur globalement bien conduit dans 82,92% des cas, a base de Chloroquine ou d'Amodiaquine
-
tolerance clinique et biologique de Fansimef dans le traitement des acces palustres
Médecine d'Afrique noire, 1992Co-Authors: A Sameekobo, J Ngogang, J Lohoue, Jean Pierre GnassounouAbstract:La tolerance du Fansimef®, l'association de mefloquine sulfadoxine et pyrimethamine (MSP), est appreciee d'apres les fluctuations de 9 parametres biologiques chez 50 patients atteints de paludisme aigu. Les tests biochimiques et hematologiques ont ete realises avant le traitement (JO) et apres celui-ci (J1, J7). Chaque patient a recu apres le diagnostic parasitologique une dose unique de MSP a raison de 1/2 cp/10 kg sans depasser 2 cp. Les resultats revelent une normalisation nette des taux d'hematocrite et de glycemie et une absence de perturbations des autres constantes biologiques explorees
H K Webster - One of the best experts on this subject based on the ideXlab platform.
-
prevention of plasmodium falciparum malaria by Fansimef and lariam in the northeastern part of thailand
Southeast Asian Journal of Tropical Medicine and Public Health, 1993Co-Authors: C Eamsila, M L Mittelholzer, P Singharaj, P Yooyen, P Chatnugrob, Nopavong Na Ayuthya A, H K Webster, R Lasserre, D SturchlerAbstract:Two studies were conduct in Thailand in order to find appropriate falciparum malaria prophylactic drug regimens. The first study was done during June - September 1987 with 363 soldiers who received Fansimef (MSP) 1 tab/week (group 1), 337 soldiers who received MSP 1 tab/2 week (group 2) and 165 soldiers who received chloroquine 300 mg base weekly plus Fansidar 1 tab/week (group 3). At the end of the study there were 9 and 13 falciparum malaria episodes in groups 1 and 2, respectively, with incidence rates of 0.8 and 1.8 cases/100 person-months (P-M). In group 3, the corresponding values were 30 episodes and an incidence of 7.2/100 P-M. For the second study which lasted from October 1987 - January 1988 in the same area, 498 soldiers were given Fansimef 1/2 tab/week (group 4), 499 soldiers were given Lariam 1/2 tab/week (group 5) and 247 soldiers were given chloroquine plus Fansidar (group 6). Thirty malaria episodes were found in group 4, for an incidence of 2.0/100 P-M. In group 5, 23 episodes were found, for an incidence of 1.6/100 P-M. In group 6, 74 episodes occurred, ie an incidence of 12.2/100 P-M. The incidence rates of malaria among Fansimef 1 tab weekly, Fansimef half dose weekly or Lariam half dose weekly were not significantly different but were different from chloroquine plus Fansidar groups. Adverse events in each group were mild.
-
quantitation of Fansimef components mefloquine sulfadoxine pyrimethamine in human plasma by two high performance liquid chromatographic methods
Therapeutic Drug Monitoring, 1991Co-Authors: Michael Edstein, Iseng Lika, T Chongsuphajaisiddhi, Arunee Sabchareon, H K WebsterAbstract:Two simple, precise, and selective high-performance liquid chromatographic methods are described for the simultaneous quantitation of mefloquine (MQ) plus pyrimethamine (PYR) or sulfadoxine (SDX) plus its principal metabolite N4-acetylsulfadoxine (N4SDX) in human plasma. After a single-step extraction, MQ plus PYR and SDX plus N4SDX including internal standards were separated using ion-paired and ion-suppression chromatography. Total run times for the assays were less than 12 min. Intraassay and interassay precision of the methods expressed as the coefficients of variation were less than 9% in plasma for the four compounds. The extraction recovery averaged 98% for MQ, 97% for PYR, 96% for SDX, and 81% for N4SDX. Plasma concentrations of the four compounds in a pediatric patient after a single oral dose of Fansimef (MQ + SDX + PYR) were determined to demonstrate the clinical application of the methods.
M L Mittelholzer - One of the best experts on this subject based on the ideXlab platform.
-
prevention of plasmodium falciparum malaria by Fansimef and lariam in the northeastern part of thailand
Southeast Asian Journal of Tropical Medicine and Public Health, 1993Co-Authors: C Eamsila, M L Mittelholzer, P Singharaj, P Yooyen, P Chatnugrob, Nopavong Na Ayuthya A, H K Webster, R Lasserre, D SturchlerAbstract:Two studies were conduct in Thailand in order to find appropriate falciparum malaria prophylactic drug regimens. The first study was done during June - September 1987 with 363 soldiers who received Fansimef (MSP) 1 tab/week (group 1), 337 soldiers who received MSP 1 tab/2 week (group 2) and 165 soldiers who received chloroquine 300 mg base weekly plus Fansidar 1 tab/week (group 3). At the end of the study there were 9 and 13 falciparum malaria episodes in groups 1 and 2, respectively, with incidence rates of 0.8 and 1.8 cases/100 person-months (P-M). In group 3, the corresponding values were 30 episodes and an incidence of 7.2/100 P-M. For the second study which lasted from October 1987 - January 1988 in the same area, 498 soldiers were given Fansimef 1/2 tab/week (group 4), 499 soldiers were given Lariam 1/2 tab/week (group 5) and 247 soldiers were given chloroquine plus Fansidar (group 6). Thirty malaria episodes were found in group 4, for an incidence of 2.0/100 P-M. In group 5, 23 episodes were found, for an incidence of 1.6/100 P-M. In group 6, 74 episodes occurred, ie an incidence of 12.2/100 P-M. The incidence rates of malaria among Fansimef 1 tab weekly, Fansimef half dose weekly or Lariam half dose weekly were not significantly different but were different from chloroquine plus Fansidar groups. Adverse events in each group were mild.
-
mefloquine sulphadoxine pyrimethamine Fansimef roche in the prophylaxis of plasmodium falciparum malaria a double blind comparative placebo controlled study
Annals of Tropical Medicine and Parasitology, 1992Co-Authors: L A Salako, R A Adio, M L Mittelholzer, D Sturchler, O Walker, A Sowunmi, R Reberliske, U DickschatAbstract:From July 1987 to June 1988 a randomized, double-blind, comparative placebo-controlled field trial was conducted in a group of villages near Ibadan, Nigeria. The aim of the study was to assess the ...
-
Fansimef for prophylaxis of malaria a double blind randomized placebo controlled trial
Southeast Asian Journal of Tropical Medicine and Public Health, 1992Co-Authors: D Bunnag, S Malikul, S Chittamas, D Chindanond, T Harinasuta, M Fernex, M L Mittelholzer, S Kristiansen, D SturchlerAbstract:At a time when Fansimef'li', the fixed combination of mefloquine, sulfadoxine and pyri methamine was considered for prophylaxis of falciparum malaria, a randomized double-blind study comparing the efficacy and tolerability of Fansimef'li' with that of Lariam® (mefloquine), Fan sidar®, chloroquine and placebo in malaria prophylaxis was performed in Thailand from July 1987 to January 1988. The study population of 602 adult males was recruited in Pak Tongchai District, some 360 km North-East of Bangkok, where multiresistant P. Jalciparum is endemic. All active treatments and placebo were given once weekly for 24 weeks with doses as follows: Fansimef: 125 mg mefloquine + 250 mg sulfadoxine + 12.5 mg pyrimethamine (I half-strength tablet); Lariam: 125 mg mefloquine (I half-strength tablet); Fansidar: 500 mg sulfadoxine + 25 mg pyrimethamine; chloroquine; 300 mg. A loading dose of 2 half-strength tablets was given in the Fansimef group in weeks I and 2 and in the Lariam group in weeks I to 4. The incidence of acute episodes of P. Jalciparum per 100 person months of prophylaxis was 0.17 each in the Fansimef and the Lariam groups, 1.18 in the Fansidar group, 0.69 in the chloroquine group and 0.64 in the placebo group (differences statistically not significant). Clinically adverse events were reported by 170 subjects (Fansimef 28, Lariam 29, Fansidar 41, choroquine 43, placebo 29; differences statistically not significant). The most frequent adverse events in all groups were headache, sleepiness, dizziness and weakness. There were five adverse events that led to premature discontinuation: I each in the placebo, chloroquine and Fansidar groups and 2 in the Lariam group (breathing difficulties, dizziness, dull head, feeling feverish, weakness and "less active"). In this setting Fansimef and Lariam offered an approximately four-fold higher protection than Fansidar or chloroquine which resembled placebo in their effect. The safety of low Fansimef and Lariam prophylactic doses was similar to placebo.
U Dickschat - One of the best experts on this subject based on the ideXlab platform.
-
mefloquine sulphadoxine pyrimethamine Fansimef roche in the prophylaxis of plasmodium falciparum malaria a double blind comparative placebo controlled study
Annals of Tropical Medicine and Parasitology, 1992Co-Authors: L A Salako, R A Adio, M L Mittelholzer, D Sturchler, O Walker, A Sowunmi, R Reberliske, U DickschatAbstract:From July 1987 to June 1988 a randomized, double-blind, comparative placebo-controlled field trial was conducted in a group of villages near Ibadan, Nigeria. The aim of the study was to assess the ...
